Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Radiation in Androgen Ablated Locally Advanced Prostate Cancer
NCT02911350Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- May 2000
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in prostate cancer (PCa), sponsored by NYU Langone Health. Primary endpoints: Maximum Tolerated Dose at 8 weeks and Number of participants with qualitative and quantitative toxicities at 8 months. Started May 2000; status: completed.
02
Drugs
paclitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02911350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911350.